Patents Examined by Alana Harris Dent
  • Patent number: 8980638
    Abstract: Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: March 17, 2015
    Assignee: University of Massachusetts
    Inventor: Zhong Jiang
  • Patent number: 8974792
    Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: March 10, 2015
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Marie Alix Poul
  • Patent number: 8975030
    Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: March 10, 2015
    Assignees: Tsinghua University, Protgen Ltd.
    Inventors: Yongzhang Luo, Xiaomin Song, Xiaofeng Wang, Wei Zhuo, Guodong Chang, Yan Fu
  • Patent number: 8951744
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 10, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Patent number: 8946169
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: February 3, 2015
    Assignee: NantBioScience, Inc.
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • Patent number: 8945570
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Patent number: 8936914
    Abstract: The present invention provides methods of aiding in a renal cell carcinoma prognosis that include quantifying expressed carbonic anhydrase in samples derived from renal cell carcinoma patients. The methods also identify patients that are likely to respond positively to selected courses of treatment. The invention further provides related computer program products.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: January 20, 2015
    Assignee: The Regents of the University of California
    Inventors: Matthew H. T. Bui, David Seligson, Arie S. Belldegrun
  • Patent number: 8916204
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 23, 2014
    Assignee: Abraxis BioSciences, LLC
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • Patent number: 8883966
    Abstract: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: November 11, 2014
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Katsunori Imai, Yusuke Nakamura, Takuya Tsunoda
  • Patent number: 8865413
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: October 21, 2014
    Assignee: Celera Corporation
    Inventors: Bruno Domon, Ian McCaffery, Vaibhav Narayan, Scott Patterson
  • Patent number: 8865646
    Abstract: The present invention relates to dietary compositions comprising reduced level of methionine, tryptophan, all amino acids, or protein, dietary compositions comprising glycerol as a substitute for monosaccharides, disaccharides, and polysaccharides, and hypocaloric or calorie free diets with reduced level of energy, carbohydrates, or protein. Also disclosed are methods of using these compositions and diets, as well as fasting, to protect subjects against chemotherapy, radiotherapy, oxidative stress, or aging.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: October 21, 2014
    Assignee: University of South California
    Inventor: Valter Longo
  • Patent number: 8841083
    Abstract: Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: September 23, 2014
    Assignees: California Institute of Technology, Indi Molecular, Inc.
    Inventors: James R. Heath, Heather Dawn Agnew, Suresh Mark Pitram
  • Patent number: 8808698
    Abstract: The present invention is directed to compositions and methods for inhibiting the development of new lymphatic vessels, and for inhibiting tumor cell dissemination through the lymphatics. In preferred embodiments, the present invention utilizes agents that inhibit the specific binding of integrin alpha4beta1 (?4?1, VLA-4) to one or more of its ligands. The invention further relates to methods for screening test compounds for their ability to inhibit undesirable lymphangiogenesis and/or tumor metastasis.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: August 19, 2014
    Assignee: The Regents of the University of California
    Inventors: Judith Varner, Barbara Garmy-Susini
  • Patent number: 8802631
    Abstract: The invention is based on the discovery that STM/Hop promotes proliferation of human glioblastoma-derived cells but not of normal astrocytes and that the proliferation requires the binding of STM/Hop to PrPc. The invention is directed to methods for treating cancer which rely on interfering with the Hop-PrPc interaction and to peptides, and antibodies raised against the peptides, which directly provide that interference. The invention is further based on the discovery that STI1230-245 peptide and its human homologue Hop23o-245 provide the desired interference with the STI1/Hop-PrPc interaction and inhibit the STI 1/Hop-induced proliferation of glioma and glioblastoma cells. The invention is thus further directed to methods of treating cancer that employ these peptides and functional derivatives thereof, and antibodies directed to the peptides and derivatives. The invention is further directed to means of treating cancer which involve reducing the effective amount of Hop or reducing the expression of Hop.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: August 12, 2014
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Rafael Bierig Erlich, Luciana Chiarini, Vilma R. Martins, Rafael Linden, Vivaldo Moura Neto
  • Patent number: 8784840
    Abstract: The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-?B activity. The modulators may be used, for example, in the treatment of NF-?B-mediated diseases, conditions, and injuries.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: July 22, 2014
    Assignee: The Cleveland Clinic Foundation
    Inventor: Andrei V. Gudkov
  • Patent number: 8778606
    Abstract: The at home cancer test permits a layperson to qualitatively test for the presence of carcinoma in the privacy of their home. The test includes a test strip coated or impregnated with at least one monoclonal antibody that binds to ?-hCG/CGH found in the patient's urine, together with a chromophore that provides a color indicator when such binding takes place. The at-home cancer test may comprise a kit containing one or more of the following: a test strip with a tab that can be gripped by the user while the strip is placed in a stream of urine; a cup for collecting urine and a test strip that may be partially immersed in the cup; and a cup for collecting urine, a test strip, and a medicine dropper or pipette for transferring the urine to the test strip.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: July 15, 2014
    Inventor: John A. Swetledge
  • Patent number: 8771963
    Abstract: In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, ECT2, CDC45L and DKK1 are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: July 8, 2014
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • Patent number: 8771691
    Abstract: The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: July 8, 2014
    Assignee: Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Patricia Forgez, Marco Alifano
  • Patent number: 8759493
    Abstract: A new gene —MN— and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: June 24, 2014
    Assignee: Institute of Virology Slovak Academy of Sciences
    Inventors: Jan Zavada, Silvia Pastorekova, Jaromir Pastorek
  • Patent number: 8741306
    Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: June 3, 2014
    Assignee: The Regents of the University of California
    Inventors: Arie Belldegrun, Cho-Lea Tso